40 undervalued Healthcare growth stocks (Nov 2026)
40 undervalued Healthcare growth stocks by the Lician Quant rating as of Nov 4, 2026, including GlaxoSmithKline PLC ADR (GSK), Neurocrine Biosciences Inc (NBIX), Encompass Health Corp (EHC). Valuation and Growth grades both B or better, rated Buy or Strong Buy: growing faster than sector peers without paying up for it.
Open this screen in the full screener to add filters, sort by any factor and save it.
40 stocks · Strong Buy or Buy · Healthcare · Valuation ≥ B · Growth ≥ B
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1AVAHAveanna Healthcare Holdings Inc | 4.99Strong Buy | A | A- | B+ | A | A+ | $2.9B | 10.6 | +19.5% | — | 10.2% | Nov 12 |
| 2BTSGBrightSpring Health Services, Inc. Common Stock | 4.96Strong Buy | A- | A- | B- | A | — | $11.6B | 28.4 | +22.9% | — | 12.0% | — |
| 3PACSPACS Group, Inc. | 4.94Strong Buy | B+ | A | A- | A | B | $7.6B | 28.1 | +16.6% | — | — | — |
| 4ASTHAstrana Health Inc | 4.93Strong Buy | A+ | A | B | C | A+ | $1.8B | 44.0 | +58.9% | — | 8.0% | Nov 5 |
| 5GMEDGlobus Medical | 4.91Strong Buy | A+ | A- | A | C | A- | $8.6B | 16.1 | +19.7% | — | 7.3% | Nov 5 |
| 6HRMYHarmony Biosciences Holdings | 4.91Strong Buy | A+ | B | A | C+ | A- | $2.2B | 12.3 | +24.3% | — | — | Nov 4 |
| 7NUTXNutex Health Inc | 4.90Strong Buy | A+ | A- | A | B- | B- | $1.4B | 7.3 | +6.9% | — | — | Nov 5 |
| 8INVAInnoviva Inc | 4.89Strong Buy | A+ | B+ | A+ | C- | A- | $1.5B | 4.3 | +18.8% | — | 10.5% | Nov 4 |
| 9NBIXNeurocrine Biosciences Inc | 4.87Strong Buy | B+ | A | A+ | B- | B | $14.7B | 21.0 | +38.0% | — | 6.6% | — |
| 10PNTGPennant Group Inc | 4.85Strong Buy | A- | B+ | B+ | B+ | B+ | $1.4B | 43.7 | +37.9% | — | — | Nov 4 |
| 11ADUSAddus HomeCare Corporation | 4.84Strong Buy | A+ | B | B | B | A- | $2.3B | 21.7 | +15.9% | — | — | — |
| 12MGTXMeiraGTx Holdings PLC | 4.82Strong Buy | A | A+ | A+ | D | B- | $897M | 11.4 | +948.3% | — | 17.6% | Nov 12 |
| 13RIGLRigel Pharmaceuticals Inc | 4.82Strong Buy | A+ | B+ | A+ | A | D- | $895M | 2.8 | +3.3% | — | 18.3% | Nov 5 |
| 14CRONCronos Group Inc | 4.80Strong Buy | A | A- | B+ | B+ | B- | $1.2B | 17.6 | +37.5% | — | 1.9% | Nov 5 |
| 15EHCEncompass Health Corp | 4.79Strong Buy | B+ | B+ | A | B+ | C+ | $12.7B | 20.4 | +9.5% | 0.72% | 3.4% | — |
| 16PDEXPro-Dex Inc | 4.79Strong Buy | A | A- | B+ | C+ | A- | $184M | 13.4 | +16.5% | — | 13.0% | — |
| 17ACADACADIA Pharmaceuticals Inc | 4.75Strong Buy | A | A- | A+ | D | B+ | $3.3B | 8.7 | +11.8% | — | 7.9% | Nov 4 |
| 18GSKGlaxoSmithKline PLC ADR | 4.72Strong Buy | A | B | A | C- | — | $99.3B | 13.2 | +7.4% | 3.50% | 0.4% | — |
| 19AUPHAurinia Pharmaceuticals Inc | 4.71Strong Buy | B+ | A | A+ | B- | D+ | $2.1B | 6.8 | +21.0% | — | 5.9% | — |
| 20ANIPANI Pharmaceuticals Inc | 4.67Strong Buy | A+ | A | A | D | C+ | $1.6B | 14.8 | +30.9% | — | 22.7% | Nov 5 |
| 21WAYWaystar Holding Corp. Common Stock | 4.63Strong Buy | A- | B | A- | B | C+ | $5.5B | 40.9 | +19.2% | — | — | — |
| 22ENSGThe Ensign Group Inc | 4.61Strong Buy | A- | B | B | C | A | $10.2B | 27.0 | +18.9% | 0.16% | 2.5% | — |
| 23ZVRAZevra Therapeutics Inc. | 4.59Strong Buy | A- | A+ | A+ | C | D+ | $582M | 10.0 | +119.4% | — | — | — |
| 24PHRPhreesia Inc | 4.58Strong Buy | A+ | A- | B | B- | C | $748M | 71.6 | +12.9% | — | 5.4% | Dec 14 |
| 25VCYTVeracyte Inc | 4.55Strong Buy | B+ | A- | A | A- | D- | $3.5B | 30.3 | +17.3% | — | — | Nov 4 |
Showing 25 of 40
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar
Growth at a fair price in other sectors
About this screen
- Which are the top undervalued Healthcare growth stocks?
- As of Nov 4, 2026, the highest ranked are Aveanna Healthcare Holdings Inc (AVAH, rating 4.99); BrightSpring Health Services, Inc. Common Stock (BTSG, rating 4.96); PACS Group, Inc. (PACS, rating 4.94); Astrana Health Inc (ASTH, rating 4.93); Globus Medical (GMED, rating 4.91). 40 stocks pass the screen in total.
- What does this screen look for?
- Valuation and Growth grades both B or better, rated Buy or Strong Buy: growing faster than sector peers without paying up for it.
- How is the Lician Quant rating calculated?
- Each stock gets five factor grades (Valuation, Growth, Profitability, Momentum, EPS Revisions) from A+ to F by ranking its metrics against the other stocks in its sector. The rating (1.00 to 5.00) is the equal-weight average of the factor scores, re-ranked within the sector: 4.50 and up is Strong Buy, 3.50 Buy, 2.50 Hold, 1.50 Sell, below that Strong Sell.
- How often is the list updated?
- After every US trading day, from SEC filings, EODHD prices and analyst estimates; this list is from the quant run of Nov 4, 2026. Short interest follows FINRA's twice-monthly settlement dates.